Cartesian Therapeutics, Inc. (United States)

Cartesian Therapeutics granted a new employee an option to purchase 3,864 shares of common stock at $13.12 per share, vesting 25% on Sept. 3, 2025, and fully vested by Sept. 3, 2028, under the Amended and Restated 2018 Employment Inducement Incentive Award Plan.

Cartesian Therapeutics has initiated a phase 1 trial for Descartes-15, a next-gen autologous mRNA-engineered CAR-T therapy targeting BCMA for relapsed/refractory multiple myeloma, featuring predictable pharmacokinetics and enhanced CAR stability, with outpatient delivery potential. Preclinical data shows Descartes-15 outperforming Descartes-08 in CAR expression and target-specific killing. The trial aims to assess safety and tolerability, with plans to expand to autoimmune disease treatment.